| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Clostripain targets peptide bonds, specifically cleaving peptides at the C-terminal side of arginine residues. Lysine bonds are also cleaved. It is a specific targeting arginine carboxypeptide key protease. Its "target" is the peptide bonds adjacent to arginine and lysine residues in proteins and peptides.
|
|---|---|
| ln Vitro |
In vitro, Clostripain is used as a research tool for protein digestion and peptide mapping. It is a potent and highly specific cysteine protease with significant applications in biotechnology and biomedical research. Its activity is measured by its ability to cleave peptide bonds at arginine residues, which can be monitored by gel electrophoresis or HPLC.
|
| ln Vivo |
In vivo, Clostripain is not administered as a therapeutic agent. It is a bacterial enzyme used in research applications. Its proteolytic activity is studied in the context of protein structure and function, and it is used as a tool for protein sequencing and analysis.
|
| Enzyme Assay |
In vitro enzyme assays with Clostripain typically involve measuring its protease activity using synthetic substrates such as benzoyl-arginine ethyl ester (BAEE) or chromogenic substrates. The assay involves incubating the enzyme with the substrate in appropriate buffer (pH 7.4-7.8) at 37°C, and monitoring the release of product by spectrophotometry.
|
| Cell Assay |
Clostripain is not typically used in cell culture experiments as a bioactive compound for treating cells. However, it may be used to digest extracellular matrix components or to prepare protein samples for analysis. Its primary use is in biochemical research for protein digestion and peptide mapping.
|
| Animal Protocol |
In vivo animal experiments with Clostripain are not performed as the enzyme is used as a research tool in vitro. Its proteolytic activity is studied in biochemical assays, not in animal models. It is a bacterial enzyme isolated from Clostridium histolyticum culture filtrate.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Clostripain are not relevant as it is an in vitro research tool, not a therapeutic agent. As a bacterial enzyme, it is not administered to animals for therapeutic purposes. Its stability and activity are characterized in vitro under controlled conditions (pH 7.4-7.8).
|
| Toxicity/Toxicokinetics |
Clostripain is handled as a laboratory reagent. It may cause allergic reactions in sensitive individuals. Standard laboratory safety practices, including the use of gloves and eye protection, should be followed when handling. It has a molecular weight of approximately 53.0 kDa (holoenzyme), with an isoelectric point of 4.8-4.9.
|
| References |
[1]. Mitchell WM, et al. Purification and properties of clostridiopeptidase B (Clostripain). J Biol Chem. 1968 Sep 25;243(18):4683-92.
|
| Additional Infomation |
Clostripain (Clostridiopeptidase B) is a proteolytic enzyme from Clostridium histolyticum that specifically cleaves peptides at the C-terminal side of arginine residues. It has esterase, amidase, and protease activities and is used in biotechnology and biomedical research for protein digestion and peptide mapping. It is not a drug and has no therapeutic indications.
|
| Exact Mass |
560.094
|
|---|---|
| CAS # |
9028-00-6
|
| PubChem CID |
168010009
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
751.6±60.0 °C at 760 mmHg
|
| Flash Point |
408.4±32.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| LogP |
4.55
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
54
|
| Heavy Atom Count |
198
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[HH].[HH].[HH].[HH].[HH].[HH].CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CCC.CC(C)CCC(CC(C)C)O.CC(C)CCC(CC(C)C)O.CC(C)CCC(CC(C)C)O.CC(C)CCC(CC(C)C)O.CC(C)CCC(CC(C)C)O.CC(C)CCC(CC(C)C)O.CC(C)CC=CCC(C)C.CC(C)CC=CCC(C)C.CC(C)CC=CCC(C)C.CC(C)CC=CCC(C)C.CC(C)CC=CCC(C)C.CC(C)CC=CCC(C)C
|
| InChi Key |
SRMJIROQHUCOER-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/6C10H22O.6C10H20.24C3H8.6H2/c6*1-8(2)5-6-10(11)7-9(3)4;6*1-9(2)7-5-6-8-10(3)4;24*1-3-2;;;;;;/h6*8-11H,5-7H2,1-4H3;6*5-6,9-10H,7-8H2,1-4H3;24*3H2,1-2H3;6*1H
|
| Chemical Name |
2,7-dimethyloctan-4-ol;2,7-dimethyloct-4-ene;molecular hydrogen;propane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
